article thumbnail

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

DAIC

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104
article thumbnail

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

DAIC

a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. F.A.C.C.

article thumbnail

Researchers develop nanoparticle technology for targeted diagnosis and treatment of atherosclerosis

Science Daily - Heart Disease

A team developed a nanoparticle technology that offers an effective solution to diagnose and treat atherosclerosis, in a non-invasive manner.

article thumbnail

HeartFlow Initiates DECIDE Registry to Evaluate Utility of HeartFlow AI-Enabled Plaque Analysis for Patients with Suspected Coronary Artery Disease

DAIC

a leader in AI-driven healthcare technology, announced the launch of the DECIDE Registry, the largest prospective registry of its kind, with the first site initiated, Cone Health Care. 2 “Data from the DECODE study shows the value of using Plaque Analysis. 2 “Data from the DECODE study shows the value of using Plaque Analysis.

article thumbnail

AI Image Analysis App Receives FDA 510(k) Clearance

DAIC

The CaRi-Plaque technology supports non-invasive analysis of coronary anatomy and pathology from routine coronary computed tomography angiography (CCTA) scans to determine the presence, extent and severity of coronary plaques and luminal stenosis (narrowing of arteries). But with AI, we can change that.

Plaque 52
article thumbnail

Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance

DAIC

Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. The CaRi-Heart technology is in clinical use in the UK, European Union, and Australia.

article thumbnail

Heartflow Rebrands, Reaffirms Commitment to Improving CAD Care Management

DAIC

a provider of AI technology for coronary artery disease (CAD) management, recently introduced its new brand identity reflecting its focus on delivering clarity, precision and confidence in the prevention, diagnosisand treatment of CAD. tim.hodson Wed, 02/26/2025 - 10:24 Feb. 25, 2025 Heartflow, Inc. , In the U.S.,